Loading
A phase 1/2 trial of REGN5093 in non-small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT04077099 by Regeneron Pharmaceuticals, with 95 participants enrolled, started 2020-01-07 and due to reach its primary completion in 2027-07-06. Interventions recorded: REGN5093.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Regeneron and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Regeneron, Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/